Print    Email
Decrease (-) Restore Default Increase (+)

Clinical Trials

Treatment   Allergy and Immunology
Trial Title   A Phase III, Multicenter, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Response Duration & Safety of Xolair® (Omalizumab) in Patients with Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic
Description of Research   The purpose of this study is to compare the effects, good and bad, of a drug called omalizumab on CIU, along with the patients' usual antihistamine treatment.
Study Number   HSR-11-1194
Inclusion/Notes   Participants are asked to be in the study because they have chronic idiopathic urticaria (CIU), which is described as chronic hives.
Principal Investigator   Jeffrey Leflein, MD
Contact Name   Patricia Lezak, CCRC
Phone   (734) 528-0477
A Member of Trinity Health
© 2015 Trinity Health

St. Joseph Mercy Ann Arbor | 5301 McAuley Drive, Ypsilanti, MI 48197 | 734-712-3456